Gonadotropin Inhibitors
1 drugsAbout Gonadotropin
Gonadotropins are heterodimeric glycoprotein hormones, including FSH and LH, that regulate reproductive function by acting on the ovaries and testes.
Gonadotropins and their receptors are therapeutic targets, but there is currently no genetic evidence data available linking them directly to specific diseases.
There is one FDA-approved drug, CLIMARA PRO, a small molecule approved in 2003, targeting the gonadotropin system for indications beyond common disease areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Vaginal Atrophy with only 3 trials.
Top Gonadotropin Drugs
BERLEX LABS is the only company with an approved drug targeting gonadotropins.
Low competition suggests market entry opportunity, but also highlights potential challenges in clinical development.
Gonadotropin Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Gonadotropin, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
Gonadotropin Clinical Trials 255 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 71 | 56 | 5 | 10 | 92% |
| Phase 2 | 52 | 27 | 15 | 10 | 64% |
| Phase 3 | 49 | 41 | 5 | 3 | 89% |
| Phase 4 | 83 | 52 | 13 | 18 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Gonadotropin Drug Approval Timeline (2003 - 2003)
The first and only drug, CLIMARA PRO, was approved in 2003.
Lack of recent approvals indicates potential saturation or challenges in developing new gonadotropin-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 208 clinical trials targeting Gonadotropin.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities